Group 1 - As of July 28, 2025, the closing price of Dirui Medical (300396) was 14.64 yuan, down 0.41%, with a turnover rate of 1.72%, trading volume of 46,900 shares, and a transaction amount of 68.6996 million yuan [1] - The company has faced criticism from investors regarding its performance, with concerns raised about the management's effectiveness leading to losses over the past year [2] - The company’s main business involves the research, production, sales, and service of medical testing instruments and related reagents, and it is committed to addressing public health needs [2] Group 2 - On July 28, the capital flow for Dirui Medical indicated a net outflow of 9.0785 million yuan from major funds, while retail investors saw a net inflow of 7.3176 million yuan [3][4] - The company has not developed products for the detection of the Chikungunya virus, despite inquiries from investors regarding its potential contributions to current public health issues [2]

Market Overview - The Shanghai Composite Index closed at 3605.73 points, above the six-month moving average, with an increase of 0.65% [1] - The total trading volume of A-shares reached 1,873.88 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 232 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Zhifei Biological Products (12.29%) - Jiexun Feihong (6.69%) - Hongtaiyang (6.56%) [1] Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Chanyi Intelligent - Donghu High-tech - Dingxin Communications [1] Performance of Selected Stocks - Zhifei Biological Products: Today's increase of 20.01%, turnover rate of 11.40%, latest price at 24.77 yuan [1] - Jiexun Feihong: Today's increase of 7.18%, turnover rate of 12.67%, latest price at 9.11 yuan [1] - Hongtaiyang: Today's increase of 7.44%, turnover rate of 8.62%, latest price at 7.08 yuan [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Dirui Medical, indicating a significant decline in revenue and profit for the first quarter of 2025 compared to the previous year [1][2] - Dirui Medical's closing stock price is 14.13 yuan, with a decline of 3.55%, resulting in a rolling PE ratio of 107.63 times, which is significantly higher than the industry average of 53.52 times and the median of 37.14 times [1][2] - The company has a total market capitalization of 3.853 billion yuan, ranking 105th in the medical device industry based on PE ratio [1][2] Group 2 - As of March 31, 2025, Dirui Medical has 17,877 shareholders, a decrease of 209 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Dirui Medical includes the research, production, marketing, and service of medical testing instruments and related reagents, with key products in various analysis areas [1] - The company holds 213 patents, including 136 invention patents and 96 software copyrights [1] Group 3 - In the latest quarterly report for Q1 2025, Dirui Medical reported an operating income of 182 million yuan, a year-on-year decrease of 72.47%, and a net profit of 15.6787 million yuan, down 87.13%, with a gross profit margin of 42.78% [1]

Core Insights - The in vitro diagnostics (IVD) industry is a crucial component of modern healthcare, providing essential data for disease prevention, diagnosis, and treatment through various testing methods [1][5][10] - China's IVD market has surpassed 120 billion yuan in 2024, with a projected growth to 165 billion yuan by 2029, reflecting a compound annual growth rate of 5-8% [1][10][19] - The industry is experiencing significant domestic substitution, with over 80% of Class III diagnostic products being domestically produced, while the share of imported products has decreased from 29.3% to 19.5% from 2021 to 2024 [1][14] Industry Overview - IVD encompasses several testing methods, including biochemical, immunological, molecular, microbiological, blood diagnostics, and point-of-care testing (POCT) [2][5] - The industry is transitioning from scale expansion to high-quality development, driven by government policies and technological innovations [5][21] Policy and Regulatory Environment - Recent government policies, such as the "14th Five-Year Plan for Bioeconomic Development" and the "Comprehensive Action Plan for Improving Medical Quality (2023-2025)," provide a strong impetus for the IVD industry [5][7] - The introduction of the "List of In Vitro Diagnostic Reagents Exempt from Clinical Trials (2025)" has expanded the range of products available in the market [7] Market Dynamics - The IVD industry is characterized by a multi-tiered market structure, with foreign giants dominating the high-end market and domestic leaders gradually increasing their market share [15][19] - The competitive landscape is evolving, with leading companies like Mindray Medical and New Industry Bio showing strong performance, while former leaders in COVID-19 testing, such as Da An Gene and BGI, are seeking business transformation [19][20] Growth Trends - The IVD industry is witnessing a shift towards precision and intelligent diagnostics, with advancements in molecular diagnostics, chemiluminescence, and POCT technologies [21][22] - The integration of AI and big data is enhancing diagnostic efficiency, while the demand for home health management and early cancer screening is rising due to an aging population [21][24] Competitive Landscape - The first tier of the market is dominated by international giants like Roche and Abbott, while domestic leaders such as Mindray and New Industry Bio are gaining traction in immunological and molecular diagnostics [15][19] - The market is seeing increased consolidation, with leading companies acquiring smaller firms to enhance their technological capabilities [23] Registration and Product Development - The registration of IVD products has been robust, with a compound annual growth rate of 25.3% from 2021 to 2024, indicating a vibrant development in the sector [14] - In 2024, the registration of domestic Class III diagnostic products reached 533, accounting for 80.5% of total IVD product registrations [14]

Group 1 - The company expects a net loss of between 22 million and 33 million RMB for the current reporting period, compared to a profit of 165.24 million RMB in the same period last year [1] - The net profit after deducting non-recurring gains and losses is expected to be a loss of between 26 million and 39 million RMB, compared to a profit of 162.36 million RMB in the previous year [1] - The significant decline in net profit is attributed to lower-than-expected installation and reagent volume of the company's instrument products in the domestic market, despite a relatively stable market environment [1][2] Group 2 - The company has communicated with the accounting firm regarding the performance forecast, and there are no significant disagreements regarding the forecast for this reporting period [1] - The company has recognized impairment losses totaling approximately 22.42 million RMB, which has significantly increased compared to the same period last year, impacting the net profit attributable to shareholders [2]

Meeting Details - The second meeting of the sixth Supervisory Board of Dirui Medical Technology Co., Ltd. was held on July 21, 2025, combining on-site and communication methods, with all three supervisors present [1][2] - The meeting was legally valid as it complied with the company's articles of association [1] Resolutions Passed - The Supervisory Board unanimously approved the proposal for asset impairment provision, confirming it aligns with accounting standards and reflects the company's financial information accurately [1][2] - The voting result for the asset impairment provision was 3 votes in favor, 0 against, and 0 abstentions, representing 100% of valid voting rights [2] - The Supervisory Board also unanimously approved the proposal to reappoint Da Xin Accounting Firm as the auditing institution for the 2025 fiscal year, affirming its independence and capability [2] - The voting result for the reappointment of the auditing firm was also 3 votes in favor, 0 against, and 0 abstentions, representing 100% of valid voting rights [2] - This proposal will be submitted for approval at the company's shareholders' meeting [2] Reference Documents - The resolutions from the second temporary meeting of the sixth Supervisory Board are available for review [2]

迪瑞医疗科技股份有限公司 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-027 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 会。 了《关于召开 2025 年第一次临时股东大会的议案》，本次会议的召开符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 （3）本公司聘请的律师。 （1）现场会议召开时间：2025 年 8 月 7 日（星期四）14:40。 （2）网络投票时间：2025 年 8 月 7 日； 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 8 月 7 日的交 易时间，即 9:15—9:25、9:30-11:30 和 13:00—15:00。 通过互联网投票系统进行网络投票的开始时间为 2025 年 8 月 7 日 09:15， 结束时间为 2025 年 8 月 7 日 15:00。 （1）现场投票：股东本人出席现场会议或者通过授权委托书（详见附件三） 委托他人出席现场会议。 （2）网络投票：公司将通过深交所交易系统和互联网投票系 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-028 迪瑞医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于 2025 年 7 月 21 日召开 的第六届董事会第二次临时会议和第六届监事会第二次临时会议，审议通过了 《关于续聘 2025 年度审计机构的议案》，公司拟聘任大信会计师事务所（特殊 普通合伙）（以下简称"大信所"）为公司 2025 年度财务报告及内部控制的审 计机构，聘期为一年。2025 年度审计费用由董事会提请股东大会授权公司管理 层根据具体审计要求和审计范围与大信所协商确定，本事项需提交公司股东大会 审议批准。现将相关情况公告如下： 一、拟续聘会计师事务所事项的情况说明 大信会计师事务所具备会计师事务所执业证书和证券、期货相关业务许可证， 该公司在执业过程中坚持独立审计原则，能按时为公司出具各项专业报告，报告 内容客观、公正，表现了良好的职业操守和业务素质。综合考虑该所的审计质量 与服务水平情况，拟续聘大信会计师事务所作为公司 2025 年度审计机构，负责 公司 ...

上述非独立董事候选人需提交公司 2025 年第一次临时股东大会审议，采用 累积投票制选举产生公司第六届董事会非独立董事。 宋清先生、秦锋先生、林茂亮先生不担任董事职务后，亦不在公司担任任何 职务。王学敏先生不担任董事职务后，仍在公司担任高级管理人员职务。 上述人员担任董事职务原定任期为第六届董事会届满之日（2026 年 12 月 25 日）止。截至本公告披露日，宋清先生、秦锋先生、林茂亮先生未持有公司股份， 王学敏先生持有公司股份 91,211 股，以上人员不存在应当履行而未履行的承诺 事项。宋清先生、秦锋先生、王学敏先生、林茂亮先生将继续遵守《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-026 迪瑞医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于 2025 年 7 月 21 日召开 了第六届董事会第二次临时会议，审议通过了《关于变更公司董事的议案》，现 将具体 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-029 迪瑞医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于 2025 年 7 月 21 日召开 了第六届董事会第二次临时会议，审议通过了《关于计提资产减值准备的议案》。 公司根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》以及公司相关会计政策的规 定，基于谨慎性原则，为真实、准确反映公司财务状况、资产价值及经营成果， 公司对截至 2025 年 6 月 30 日合并报表范围内的各类资产进行了全面清查。对各 项资产减值的可能性进行了充分的评估和分析，判断存在可能发生减值的迹象， 确定了需计提的资产减值准备。现将有关情况列示如下： 一、本次计提资产减值准备情况概述 根据《企业会计准则第 8 号——资产减值》及公司会计政策的相关规定，为 更加客观、公正地反映公司的财务状况和资产价值，基于谨慎性原则，公司对合 并报表范围内截至 2025 年 6 月 30 日的各类资产进行 ...